Breast reduction mammoplasty (BRM) is among the most commonly performed procedures in plastic
surgery. However, postoperative hematoma is one of the most common complications following
BRM. Hematoma-related complications include unplanned surgery, need for blood transfusion,
wound healing issues, and unfavorable surgical outcomes.
Tranexamic acid has emerged in the literature as a promising agent that reduces perioperative
blood loss and need for transfusion. However, despite its consistently reported efficacy, low
cost, and favorable safety profile, tranexamic acid remains underutilized in plastic surgery.
The investigators propose a prospective, double-blinded randomized controlled study of the
efficacy of tranexamic acid in reducing hematoma development in patients undergoing reduction
mammoplasty. The investigators hope to contribute to the growing body of literature
supporting tranexamic acid to reduce unwanted surgical bleeding.